Orange Book product · Brand (NDA)

ZTLIDO

LIDOCAINE

Brand (NDA)NDA 207962TE ABRX SCILEX PHARMS

Feb 28, 2018

Approved

Brand (NDA)

Application

TE code

Listed patents

Approval
FDA approval date of this drug product.
Feb 28, 2018
8 yr 5 mo ago
Today
Patent 10765640 expires
Listed drug product patent expiration.
May 10, 2031
in 5 yr
Patent 10765749 expires
Listed drug product patent expiration.
May 10, 2031
in 5 yr
Patent 11278623 expires
Listed drug product patent expiration.
May 10, 2031
in 5 yr
Patent 11786455 expires
Listed drug product patent expiration.
May 10, 2031
in 5 yr
Patent 11793766 expires
Listed method-of-use patent (U-2267) expiration.
May 10, 2031
in 5 yr
Patent 9283174 expires
Listed drug product patent expiration.
May 10, 2031
in 5 yr
Patent 9925264 expires
Listed drug product patent expiration.
May 10, 2031
in 5 yr
Patent 9931403 expires
Listed drug product patent expiration.
May 10, 2031
in 5 yr

Active ingredient

LIDOCAINE

Strength

1.8%

Dosage form

PATCH

Route

TOPICAL

TE code

Application

NDA 207962

Product number

001

Marketing status

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
Patent	Expires	In	Type
10765640	May 10, 2031	in 5 yr	Product
10765749	May 10, 2031	in 5 yr	Product
11278623	May 10, 2031	in 5 yr	Product
11786455	May 10, 2031	in 5 yr	ProductU-2267
11793766	May 10, 2031	in 5 yr	U-2267
9283174	May 10, 2031	in 5 yr	Product
9925264	May 10, 2031	in 5 yr	ProductU-2267
9931403	May 10, 2031	in 5 yr	Product